drugset
drugset / Trial / NCT06956170

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT06956170 ↗

Phase 3 Active not recruiting 21 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).

Timeline

Start
2022-02-10
Primary completion
2024-05-27
Completion
2029-06-25

Outcome

Missed primary endpoint

registry Hazard Ratio (HR) 0.53 (95% CI 0.10 to 2.78) NCT06956170 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Belantamab mafodotin Monoclonal antibody — —
Comparator Bortezomib Small molecule — —
Background Dexamethasone Small molecule — —
Background Pomalidomide Other / unclassified — —

Indications

plasma cell myeloma